Skip to main content
. Author manuscript; available in PMC: 2015 Sep 8.
Published in final edited form as: Gastroenterology. 2011 Jun 24;141(4):1439–1450. doi: 10.1053/j.gastro.2011.06.046

Figure 6. Liver tumors harboring combined RB/p53 loss display chromosomal aberrations and gene deregulation indicative of advanced HCC.

Figure 6

(A) Wild-type and RB/p53-deficient livers stained for pSerH3. (B) Top, percentage of hepatocytes harboring 2N, 4N and >4N DNA content (**p=0.0018, 0.0015). Bottom, selected chromosome gain/loss images from CGH analyses. C1-2 indicates non-tumor liver tissue and T1-5 indicates liver tumor samples from mice 6-months post-DEN. (C) Gene expression data comparing 14-day old, RB/p53-deficient and wild-type DEN-treated livers. Left, changes in gene expression displayed as a heat map. Right, human liver samples (GSE6764, GSE9843, and GSE4108) clustered based on average intensities of deregulated genes in RB/p53-deficient, DEN-treated mouse livers. (D) Kaplan Meier analysis demonstrating recurrence-free survival in human tissue samples (GSE4108) clustered based on average intensities of up-regulated genes (i.e. additive gene deregulation) in RB/p53-deficient, DEN-treated mouse livers. Samples were divided into high expression (Red) or low expression (Blue) of the gene profile.